Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions

Crohn's Disease

Interventions

DRUG

AZD7798

Participants will receive IV infusion of AZD7798 as stated in arm description.

DRUG

[11C]AZ14132516

Participants will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 as stated in arm description.

Trial Locations (1)

Research Site, Stockholm